Gliknik Inc. (Gliknik)

Oncology Corporate Profile

HQ Location

801 W. Baltimore Street, Suite 501A
Baltimore, MD 21201

Company Description

Gliknik is creating new therapies for patients with cancer and immune disorders. In September 2013 Gliknik announced a significant license of GL2045, a functional recombinant mimetic of pooled human IVIG, to Pfizer Inc.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GL-0817immunotherapyHead & Neck cancerII

View additional information on product candidates here »


Recent News Headlines

There are no news items to display